CDC Releases Additional Doses of RSV Treatment Amid Rising Infections

The move aims to address the high demand and limited supply of the preventive antibody treatment, nirsevimab, as RSV infections surge in parts of the U.S.

RSV infections are rising sharply in some parts of the country, nearly filling hospital emergency departments in Georgia, Texas and some other states.
The CDC has released an additional 77,000 doses of a monoclonal antibody treatment designed to safeguard infants against the respiratory infection RSV.
The drug, called nirsevimab and sold under the brand name Beyfortus, is the first preventive antibody treatment widely available to protect healthy infants against respiratory syncytial virus, the No. 1 cause of infant hospitalization in the United States.
Demand for the RSV treatment has vastly surpassed the supply, causing frustration among parents and pediatricians.
The additional doses will be distributed immediately to hospitals and physicians through the federally funded Vaccines for Children Program and commercial payers.